Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Realini, Natalia ^a,b   Solorzano, Carlos ^a   Pagliuca, Chiara ^b   Pizzirani, Daniela ^b   Armirotti, Andrea ^b   Luciani, Rosaria ^c   Costi, Maria Paola ^c   Bandiera, Tiziano ^b   Piomelli, Daniele ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1-HEXYLCARBAMOYL-5-FLUOROURACIL; ACID CERAMIDASE; ANTINEOPLASTIC AGENT; CARMOFUR; CERAMIDE; DRUG DERIVATIVE; FLUOROURACIL;

ANIMAL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; MALE; METABOLISM; MOUSE; MULTIDRUG RESISTANCE; NEOPLASM; TUMOR CELL LINE;

ACID CERAMIDASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CERAMIDES; DRUG RESISTANCE, MULTIPLE; FLUOROURACIL; HUMANS; MALE; MICE; NEOPLASMS;

MLCS; MLOWN;

EID: 84872731428     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01035     Document Type: Article

References (37)

1. Zeidan, Y. H. & Hannun, Y. A. The acid sphingomyelinase/ceramide pathway: biomedical significance and mechanisms of regulation. Curr. Mol. Med. 10, 454-466 (2010).
2. Furuya, H., Shimizu, Y. & Kawamori, T. Sphingolipids in cancer. Cancer Metastasis Rev 30, 567-576 (2011).
3. Riboni, L. et al. Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 39, 105-113 (2002). (Pubitemid 34817051)
4. Ogretmen, B. & Hannun, Y. A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 4, 604-616 (2004). (Pubitemid 39025055)
5. Canals, D., Perry, D. M., Jenkins, R. W. & Hannun, Y. A. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases. Br. J. Pharmacol. 163, 694-712 (2011).
6. Gault, C. R., Obeid, L. M. & Hannun, Y. A. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv. Exp. Med. Biol. 688, 1-23 (2010).
7. Liu, Y. et al. Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma. J Proteome Res 9, 6044-6051 (2010).
8. Seelan, R. S. et al. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 29, 137-146 (2000).
9. Mahdy, A. E. et al. Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol. Ther. 17, 430-438 (2009).
10. Sugita, M.,Willians, M., Dulaney, J. T. &Moser, H. W. Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase. Biochim. Biophys. Acta 398, 125-131 (1975).
11. Bielawska, A. et al. (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1- propanol as an inhibitor of ceramidase. J. Biol. Chem. 271, 12646-12654 (1996).
12. Bielawska, A. et al. Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorg. Med. Chem. 16, 1032-1045 (2008). (Pubitemid 351163040)
13. Kubota, T. et al. Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. Jpn. J. Cancer Res. 82, 476-482 (1991).
14. Nishiyama, M. et al. [Inhibition of thymidylate synthetase and antiproliferative effect by 1-hexylcarbamoyl-5-fluorouracil]. Gan. To Kagaku Ryoho 15, 3109-3113 (1988).
15. Watanabe, M. et al. Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil. Langenbecks Arch. Surg. 391, 330-337 (2006). (Pubitemid 44298422)
16. Nikolova-Karakashian, M. N. & Rozenova, K. A. Ceramide in stress response. Adv. in Exp. Med. Biol. 688, 88-90 (2010).
17. Holland, W. L. et al. Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 17, 55-63 (2011).
18. Teichgraber, V. et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med. 14, 382-391 (2008). (Pubitemid 351499396)
19. Hannun, Y. A. & Obeid, L. M. Many ceramides. J. Biol. Chem. 286, 27855-27862 (2011).
20. Grabovsky, Y. & Tallarida, R. J. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J. Pharmacol. Exp. Ther. 310, 981-986 (2004). (Pubitemid 39108918)
21. Maurer, B. J., Melton, L., Billups, C., Cabot, M. C. & Reynolds, C. P. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst. 92, 1897-1909 (2000). (Pubitemid 32036920)
22. Roberts, C. G., Gurisik, E., Biden, T. J., Sutherland, R. L. & Butt, A. J. Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism. Mol. Cancer Ther. 6, 2777-2785 (2007). (Pubitemid 350064074)
23. Gouaze-Andersson, V. et al. Inhibition of acid ceramidase by a 2-substituted aminoethanol amide synergistically sensitizes prostate cancer cells to N-(4-hydroxyphenyl) retinamide. Prostate 71, 1064-1073 (2011).
24. Hoshi, A., Iigo, M., Nakamura, A., Yoshida,M. & Kuretani, K. Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumors. Gann 67, 725-731 (1976).
25. Kobari, T. et al. Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil in rats. Xenobiotica 8, 547-556 (1978). (Pubitemid 9012170)
26. Iigo, M., Nakamura, A., Kuretani, K. & Hoshi, A. Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil after oral administration in mice. Xenobiotica 10, 847-854 (1980). (Pubitemid 11203686)
27. Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer 3, 330-338 (2003). (Pubitemid 37328853)
28. Sato, S., Ueyama, T., Fukui, H.,Miyazaki, K. & Kuwano, M. [Anti-tumor effects of carmofur on human 5-FU resistant cells]. Gan. To Kagaku Ryoho 26, 1613-1616 (1999).
29. Awad, A. B., Barta, S. L., Fink, C. S. & Bradford, P. G. beta-Sitosterol enhances tamoxifen effectiveness on breast cancer cells by affecting ceramide metabolism. Mol. Nutr. Food Res. 52, 419-426 (2008).
30. Raisova,M. et al. Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. FEBS Lett. 516, 47-52 (2002).
31. Selzner, M. et al. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res. 61, 1233-1240 (2001). (Pubitemid 32174448)
32. Samsel, L. et al. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 58, 382-393 (2004). (Pubitemid 38295032)
33. Arnal-Herault, C. et al. Constitutional self-organization of adenine-uracil-derived hybrid materials. Chemistry 13, 6792-6800 (2007). (Pubitemid 47329287)
34. Solorzano, C. et al. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc. Natl. Acad. Sci USA 106, 20966-20971 (2009).
35. Snigdha, S. et al. Dietary and behavioral interventions protect against age related activation of caspase cascades in the canine brain. PLoS One 6, e24652 (2011).
36. Tallarida, R. J. & Raffa, R. B. The application of drug dose equivalence in the quantitative analysis of receptor occupation and drug combinations. Pharmacol. Ther. 127, 165-174 (2010).
37. Tallarida, R. J. Interactions between drugs and occupied receptors. Pharmacol Ther 113, 197-209 (2007). (Pubitemid 44969929)